| Literature DB >> 35855892 |
Gilbert Sterling Octavius1, Jeremiah Hilkiah Wijaya1, Alexa Ovilia Tan1, Michelle Patricia Muljono1, Shally Chandra1, Andry Juliansen1.
Abstract
Background: Little is known how COVID-19 is affecting children. Autopsies help gain an understanding of the pathophysiology of new and developing diseases. Numerous post-mortem studies had been conducted in adults with COVID-19, but few in children. Thereby, this systematic review aims to investigate the autopsy findings from pediatric COVID-19 patients.Entities:
Keywords: Autopsy; COVID-19; Pathology; Pathophysiological mechanisms; Pediatric
Year: 2022 PMID: 35855892 PMCID: PMC9281196 DOI: 10.1186/s41935-022-00288-0
Source DB: PubMed Journal: Egypt J Forensic Sci ISSN: 2090-536X
Keywords used in each database platform
| Database | Keyword or medical subject headings |
|---|---|
| MEDLINE | (((COVID-19) AND MIS-C) AND Autopsy) AND Pediatric) AND Histopathology |
| Research Square | (COVID-19 (OR) SARS-COV-2 (OR) PIMS-TS (OR) MIS-C) AND (pediatric (OR) Adolescent) AND (Autopsy (OR) Pathology) |
| Google Scholar | (COVID-19 (OR) MIS-C (OR) PIMS-TS) AND (Pediatric (OR) Adolescent) AND (Autopsy" (OR) "Histopathology) |
| PubMed | "childs"[All Fields] OR ("paediatrics"[All Fields] OR "pediatrics"[MeSH Terms] OR "pediatrics"[All Fields] OR "paediatric"[All Fields] OR "pediatric"[All Fields]) OR ("infant"[MeSH Terms] OR "infant"[All Fields] OR "infants"[All Fields] OR "infant s"[All Fields]) OR ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND "newborn"[All Fields]) OR "newborn infant"[All Fields] OR "neonatal"[All Fields] OR "neonate"[All Fields] OR "neonates"[All Fields] OR "neonatality"[All Fields] OR "neonatals"[All Fields] OR "neonates"[All Fields]) OR ("adolescences"[All Fields] OR "adolescency"[All Fields] OR "adolescent"[MeSH Terms] OR "adolescent"[All Fields] OR "adolescence"[All Fields] OR "adolescents"[All Fields] OR "adolescent s"[All Fields])) AND ("autopsied"[All Fields] OR "autopsy"[MeSH Terms] OR "autopsy"[All Fields] OR "autopsies"[All Fields] OR ("pathology"[MeSH Terms] OR "pathology"[All Fields] OR "pathologies"[All Fields] OR "pathology"[MeSH Subheading]) OR ("histopathologies"[All Fields] OR "pathology"[MeSH Subheading] OR "pathology"[All Fields] OR "histopathology"[All Fields] OR "pathology"[MeSH Terms]) OR "post-mortem"[All Fields] OR "post-humous"[All Fields] OR ("autopsy"[MeSH Terms] OR "autopsy"[All Fields] OR "necropsy"[All Fields] OR "necropsied"[All Fields] OR "necropsies"[All Fields]))) AND (allchild[Filter]) |
| Science Direct | (COVID-19 (OR) SARS-COV-2 (OR) PIMS-TS (OR) MIS-C) AND (pediatric (OR) Adolescent) AND (Autopsy (OR) Pathology) |
| Scielo | ( (COVID-19) OR (SARS-COV-2) OR (PIMS-TS) OR (MIS-C) OR (Multisystem inflammatory syndrome in children) OR (COVID-2019)) AND ((pediatric) OR (children) OR (Infant) OR (Neonate) OR (Adolescent)) AND ((Autopsy) OR (Pathology) OR (Histopathology) OR (Post-mortem) OR (Post-humous) OR (Necropsy)) |
| Medrxiv | "COVID-19 AND pediatric AND Pathology" and full text or abstract or title "Autopsy" |
| Biorxiv | (COVID-19 (OR) SARS-COV-2 (OR) PIMS-TS (OR) MIS-C) AND (pediatric (OR) Adolescent) AND (Autopsy (OR) Pathology) |
Fig. 1PRISMA flow chart of this study
Characteristic of patients demographic
| Variables | No of patients available | Median (range) | |
|---|---|---|---|
| Age (years) | 15 | 11.1 (0.6–17) | |
| Race | 8 | ||
| Caucasian | 2 (25%) | ||
| African American | 6 (75%) | ||
| Sex | 9 | ||
| Male | 2 (22.2%) | ||
| Female | 7 (77.8%) | ||
| BMI | 6 | 22.8 (11.2–31) | |
| Comorbid diseases | 5 | ||
| Edwards syndrome | 1 (20%) | ||
| Diabetes | 1 (20%) | ||
| Hypertension | 1 (20%) | ||
| Obese | 2 (40%) | ||
| First symptom onset (days) | 8 | 10 (2-27) | |
| Antibody | 1 | ||
| Positive | 1 (100%) | ||
| Nasopharyngeal PCR | 9 | ||
| Positive | 7 (77.8%) | ||
| Lab parameters | Reference range | ||
| Hemoglobin, g/dL | 7 | 10.6 (8.8–12.2) | 10–15.5 |
| Hematocrit, % | 7 | 31.7 (28.8–39.6) | 32–44 |
| Platelets, ×103 cells per μL | 7 | 252.3 (111–296) | 150–400 |
| White blood cell count, ×103 cells per mm3 | 7 | 19 (9.3–32.6) | 5–10 |
| Lymphocytes, % | 7 | 11.5 (0.79–58) | 20–40 |
| Absolute neutrophil count (K/mm3) | 6 | 62.8 (28–95) | 55–70 |
| Urea, mg/dL | 6 | 61.3 (23–122) | 5–18 |
| Creatinine, mg/dL | 6 | 0.9 (0.26–1.87) | 0.5–1.0 |
| D-dimer, ng/mL | 6 | 2532.4 (11.5–2324) | <250 |
| Troponin T, ng/mL | 6 | 0.1 (0.002–0.3) | <0.1 |
| Creatine kinase myocardial band, ng/mL | 5 | 5.76 (0.64–30.7) | 0.1–2.88 |
| Creatine kinase, U/L | 5 | 96 (50–1008) | <167 |
| Fibrinogen, mg/dL | 5 | 356 (111–513) | 200–393 |
| aPTT, s | 4 | 39.05 (36–57.9) | 25.4–38.9 |
| Ferritin, ng/mL | 4 | 707 (159–1501) | 20–200 |
| Triglycerides, mg/dL | 5 | 183.5 (59–272) | 100–129 |
| Interleukin-6, pg/mL | 1 | 4105 | 0.2–7.8 |
| Blood pH | 1 | 7.2 | 7.35–7.45 |
| Bicarbonate, mEq/L | 1 | 15.7 | 21·0–28·0 |
| PaCO2, mm Hg | 1 | 41 | 35–45 |
| PaO2, mm Hg | 1 | 60 | 80–90 |
| ScvO2, % | 1 | 87.2 | 60–85 |
| Lactate, mg/dL | 6 | 28 (14–39) | 4.5–14.4 |
| C-reactive protein, mg/L | 7 | 134.1 (1.5–266.6) | <10 |
| Erythrocyte sedimentation rate (mm/h) | 1 | 74 | <10 |
| Total protein, g/dL | 2 | 6.1 (5–7.2) | 6–8 |
| Albumin, g/dL | 7 | 3 (2.5–4.3) | 3.8–5.4 |
| Total bilirubin, mg/dL | 6 | 3.04 (0.3–11.1) | 0.3–1 |
| Direct bilirubin, mg/dL | 5 | 0.37 (0.23–9.84) | <0.2 |
| Aspartate aminotransferase, U/L | 7 | 155.9 (20–506) | 10–50 |
| Alanine aminotransferase, U/L | 7 | 142.1 (13–376) | 4–36 |
| Gamma-glutamyl transferase, U/L | 6 | 217.5 (9–479) | 5–27 |
Summary of included papers
| Principal investigator (year) | Study cohort (N)/female/( | Cause of death | Postmortem NP COVID-19 testing ( | Postmortem assessment (microscopic findings) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart | Lung | Liver | Kidney | Brain | Bone marrow | Lymph node | Skin | Spleen | Muscle | Colon | Others | ||||
| Craver et al. ( | 1/0/17/no | Eosinophilic myocarditis | Positive | Diffuse inflammatory infiltrates composed of lymphocytes, macrophages with prominent eosinophils. | Congestion, acute focal hemorrhage, and edema, but no interstitial inflammation, diffuse alveolar damage, increased intra-alveolar hemosiderin-laden macrophages, viral inclusions, or viral cytopathic changes, eosinophilic infiltrates, vasculitis, or intraparenchymal lymphoid hyperplasia. | ||||||||||
| Beaudry et al. ( | 1/1/18/yes | Positive | Diffuse lymphoplasmacytic inflammatory infiltrates, most marked in the septum. Diffuse lymphoplasmacytic inflammatory infiltrates, most marked in the septum. The inflammation clustered around and partially involved small arterioles, venules, and lymphatics but did not involve capillaries. There were only very focal areas of visible myocyte damage in the right ventricle. Myocardial injury was, in fact, more extensive and occurred too acutely to show diffuse histologic evidence. | Vascular congestion without inflammation, thrombi, or other abnormality. | Focal apoptosis of tubular cells but without frank inflammation, damage, or microthrombi. | Normal. | |||||||||
| Dolhnikoff et al. ( | 1/1/11/yes | Heart failure | Interstitial and perivascular myocardial inflammation containing lymphocytes, macrophages, a few neutrophils and eosinophils, and foci of cardiomyocyte necrosis; Myocardial necrosis indicated by C4d staining; Myocardial interstitial inflammation containing CD68+ and CD45+ cells. | Pulmonary tissue with focal exudative changes and mild pneumocyte hyperplasia; Fibrinous thrombi in small pulmonary arterioles. | Hepatic centrilobular necrosis | ATN | Reactive microglia | Lymphoid depletion and signs of hemophagocytosis. | |||||||
| de Almeida Monteiro et al. ( | 1/n.r./0.6/no | DAD. | |||||||||||||
| Bhatnagar et al. ( | 4/n.r./n.r/no | Positive (3), Not performed (1) | Interstitial pneumonitis (1), pulmonary edema (1), DAD, bronchopneumonia (1), tracheobronchitis (1), mild hemorrhage (1). | ||||||||||||
| Diorio et al. ( | 1/1/18//no | Heart failure (1) | |||||||||||||
| Duarte-Neto et al. ( | 5/4/8.5 (0.6–15)/yes (3) | Disseminated thrombosis (1), COVID-19 pneumonia (1), SARS-COV-2 myocarditis (1), SARS-COV-2 colitis (1), SARS-COV-2 meningoencephalitis (1) | Positive (1), Negative (1), n.r (3) | Interstitial edema (4), pericarditis (1), myocarditis (2), endocarditis (1), myocardial necrosis (3) | Rare cells with cytopathic change (4); Large number of megakaryocytes (2); Typical SARS-COV-2 pneumonia with exudative DAD (3); Thrombi in arterial vessels (3) and septal capillaries (4), Congestion, oedema, foci of haemorrhage (4); Angiomatoid pattern (2); Various foci of coagulative necrosis (1). | Congestion (5), centrilobular necrosis (3), arterial thrombi with ischaemic necrosis (1), sinusoids thrombi (1) syncytial metaplasia of hepatocytes (1), cholestasis (1), hemophagocytosis by Kupffer cells (1), micro/macro vesicular steatosis, multinucleation, mild portal infiltrate (1), hepatocyte binucleation (1) | ATN (5), congestion (5), fibrin thrombi in glomerular capillaries (2), nephrocalcinosis (1), mesangial cell hyperplasia (1), hyaline cast (1), exudate in the Bowman space (1), granular casts (1). | Reactive microglia (5), neuronal ischaemia (5), congestion (5), oedema (2), capillary fibrin thrombi (1), Alzheimer type II glial cells (1). | Hypercellular, hemophagocytosis, emperipolesis by megakaryocytes (1), Normocellular, normomaturative (1); Mild nuclear atypia of megakaryocytes (1). | Pulmonary lymph nodes with lymphoid hypoplasia and hemophagocytosis (1) | Normal (1) Superficial perivascular mononuclear infiltrate (3) Superficial periadnexal mononuclear infiltrate (1) | Splenitis (5), hemorrhages (5), lymphoid hypoplasia with reactive cells (5) hemophagocytosis (2), sinusoidal fibrin thrombi (1) | Myolysis (5), necrotic fibers (4) | Oedema and mild inflammation (1), colitis with dense inflammatory cell infiltration (1), arteriolar microthrombi (1), appendicitis with peritonitis (1) | parotiditis (2), adrenal carcinoma with intense necrosis (1) |
| Adam et al. ( | 2/1/11.5 (8–15)/n.r. | Positive (1), Negative (1) | Exudative and proliferative DAD, with epithelial atypia which extended throughout the respiratory epithelium (2). | Vacuolization of the cytoplasm and nucleus (1) | |||||||||||
ATN Acute tubular necrosis, DAD Diffuse alveolar damage, N Number, n.r Not reported, NP Nasopharyngeal
aWhen there are multiple patients, the data is reported in the median (range)
Postmortem examination
| Postmortem examination | Number of patients available | Median (range) | |
|---|---|---|---|
| Heart | 1 | ||
| Weight (grams) | 500 | ||
| Pericardial fluid (mL) | 80 | ||
| Lung | 2 | ||
| Weight (grams) | |||
| Right | 955 (880–1030) | ||
| Left | 835 (770–900) | ||
| Culture | 1 | ||
| | 1 (100%) | ||
| Nasopharyngeal polymerase chain reaction (PCR) test | 4 | ||
| Positive | 3 (75%) | ||
| Periodontium | 1 (25%) | ||
| Heart ultrasound | 1 | ||
| Thickening | 1 (100%) | ||
| Heart echocardiogram | 5 | ||
| Small pericardial effusion | 2 | ||
| Metastatic tumor | 1 | ||
| Patent foramen ovale | 1 | ||
| Apical ventricular septal defect | 1 | ||
| Left ventricular global hypokinesis | 1 | ||
| Dilated left ventricle | 1 | ||
| Right ventricle systolic dysfunction | 1 | ||
| Hyperechogenic coronary arteries | 1 | ||
| Coronary artery diffuse ectasia | 1 | ||
| Left anterior descending coronary artery diffuse ectasia | 1 | ||
| Computed tomography (CT) angiography | |||
| Normal | 1 (100%) | ||
| Cerebrospinal fluid (CSF) culture | |||
| Contaminated | 1 (100%) | ||
| Immunodeficiency testing | |||
| Congenital Immunodeffiency | 1 (100%) | ||
| Blood culture | 1 | ||
| Sterile | 1 (100%) | ||
| Caffeine | 1 | ||
| Positive | 1 (100%) | ||
| Naloxone | 1 | ||
| Positive | 1 (100%) | ||
| Vitreous examination | |||
| Glucose | 1 | ||
| Positive | 1 (100%) | ||
| Acetone | 1 | ||
| Positive | 1 (100%) | ||